ClinicalTrials.gg
CompletedNCT01147848Updated Jan 18, 2017Results posted

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

A Phase 3 interventional study of Fluticasone furoate/Vilanterol Inhalation Powder and Fluticasone propionate/salmeterol Inhalation Powder in Asthma, sponsored by GlaxoSmithKline. Completed at 63 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
810
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.

Enrollment
14th of 238
810 · median 93
Started
2010
with 33 others
Phase 3
61 of 262
6 open now
Registered
93rd of 262
by date

Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 14th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 61 in phase 3, and was the 93rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Asthma by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily with fluticasone propionate/salmeterol administered twice daily in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week period.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Salmeterol
  • fluticasone furoate
  • Vilanterol
  • fluticasone propionate
  • GW642444
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of asthma
  • Reversibility of at least 12% and at least 200mLs within 10-40 minutes following 2-4 inhalations of albuterol
  • of 40-85% predicted normal
  • Currently using inhaled therapy

Exclusion criteria

Exclusion Criteria:

  • History of life-threatening asthma within previous 5 years (requiring intubation and/or was associated with hypercapnoea, respiratory arrest or hypoxic seizures)
  • Respiratory infection or oral candidiasis
  • Asthma exacerbation requiring oral or that resulted in overnight hospitalisation requiring additional asthma treatment
  • Uncontrolled disease or clinical abnormality
  • Allergies
  • Taking another medication or prohibited medication
  • Night shift workers
  • Current smokers or subjects with smoking history of at least 10 pack years
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
810 participants (actual)

Study arms

  • Experimental
    Fluticasone furoate/Vilanterol (GW642444)

    Fluticasone furoate/vilanterol inhalation powder once daily + placebo inhalation powder twice daily for 24 weeks

    Drug: Fluticasone furoate/Vilanterol Inhalation Powder · Drug: Placebo (2)

  • Active comparator
    Fluticasone propionate/salmeterol

    Fluticasone propionate/salmeterol inhalation powder twice daily + placebo inhalation powder once daily for 24 weeks

    Drug: Fluticasone propionate/salmeterol Inhalation Powder · Drug: Placebo (1)

Interventions

  • DrugFluticasone furoate/Vilanterol Inhalation Powder

    Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks

  • DrugFluticasone propionate/salmeterol Inhalation Powder

    Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks

  • DrugPlacebo (1)

    Inhalation powder inhaled orally once daily for 24 weeks

  • DrugPlacebo (2)

    Inhalation powder inhaled orally twice daily for 24 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Weighted-mean 24 Hour Serial FEV1 on Day 168/Week 24

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, on Day 168/Week 24. Change from Baseline was calculated as the weighted mean of the 24-hour serial FEV1 measures on Day 168/Week 24 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.

    Time frame: Baseline and Day 168/Week 24

Secondary outcomes

  1. Serial FEV1 (0-24 Hours)

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . The pre-dose FEV1 assessment and the individual serial FEV1 assessments at Day 168/Week 24 at the indicated time points (pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 11 hours, 12 hours, 12.5 hours, 13 hours, 14 hours, 16 hours, 20 hours, 23 hours, and 24 hour s) were summarized.

    Time frame: Day 168

  2. Number of Participants With the Indicated Time to Onset of Bronchodilator Effect at Day 1

    Time to onset of bronchodilator effect at Day 1 is defined as the actual time during the 4-hour serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) measurements that the participant first meets or exceeds a 12% and 200 mL increase over Baseline and was derived at Day 1 only. Time to onset was calculated over 0 to 4 hours (5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 4 hours) post-dose. Participants who never exceeded a 12% and 200 mL increase over Baseline were censored at the actual time of their last FEV1 measurement.

    Time frame: Baseline to Day 1

  3. Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours Post First Dose (at Randomization)

    The weighted mean serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) over 0-4 hours post-dose at Baseline was derived using actual times and using the pre-dose assessment as the 0 hour measurement. Change from Baseline was calculated as the weighted mean of the 4-hour serial FEV1 measures on Day 1 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment.

    Time frame: Baseline and Randomization

  4. Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours at Day 168

    The weighted mean serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) over 0-4 hours post-dose at Baseline and Day 168 was derived using actual times and using the pre-dose assessment as the 0 hour measurement. Change from Baseline was calculated as the weighted mean of the 4-hour serial FEV1 measures on Day 168/Week 24 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment.

    Time frame: Baseline and Day 168

  5. Number of Participants Obtaining a >=12% and >=200 mL Increase From Baseline in FEV1

    The number of participants obtaining a \>=12% and \>=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated at 12-hours post-dose and at 24-hours post-dose on Day 168.

    Time frame: Baseline and Day 168

  6. Change From Baseline in Trough FEV1 at Day 168

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . Trough FEV1 is defined as the pre-dose measurement on Day 168/Week 24. Any missing data at Day 168/Week 24 was imputed using the last observation carried forward (LOCF). Baseline was the pre-dose measurement on Day 1. Change from Baseline was calculated as the pre-dose measurement on Day 168/Week 24 minus the Baseline value.

    Time frame: Baseline and Day 168

Other outcomes

  1. Baseline FEV1 by Completion Status

    Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.

    Time frame: Baseline

  2. Change From Baseline in Asthma Control Test (ACT) Scores at Day 168

    The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, "How much of the time did your asthma keep you from getting as much done at work, school or at home?", "How often have you had shortness of breath?", "How often did your asthma symptoms wake you up at night or earlier than usual in the morning?", "How often have you used your rescue inhaler or nebulizer medication (such as albuterol)?" and "How would you rate your asthma control"? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the Day 168 value minus the Baseline value.

    Time frame: Baseline and Day 168

  3. Number of Healthcare Contacts Related to Asthma or the Treatment of Asthma From Baseline to Day 168

    All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (to the general ward \[GW\] or the intensive care unit \[ICU\]) that were associated with asthma exacerbations were recorded.

    Time frame: Baseline to Day 168

  4. Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score for Participants 12 Years of Age and Older (AQLQ + 12)

    The AQLQ is a disease-specific, self-administered quality of life (QOL) questionnaire developed to evaluate the impact of asthma treatments on the QOL of asthma sufferers. The AQLQ contains 32 items in four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). The response format consists of a 7-point scale: a value of 1 indicates "total impairment"; a value of 7 indicates "no impairment." The AQLQ total score is defined as the average of the scores from all 32 questions, provided at least 90% of the questions have been answered; thus, the total score ranges from 1 (indicates "total impairment") to 7 (indicates "no impairment"). Change from Baseline was calculated as the Day 168 value minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline total AQLQ score, country, sex, age, and treatment.

    Time frame: Baseline and Day 168

  5. Percentage of Participants With "No Problems" in the EQ-5D Descriptive System Dimensions at Day 168/Week 24

    The EQ-5D is a standardized, 2-part, self-assessment instrument, designed for self-completion, used to measure health outcome. The first part consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is measured by a three-point Likert scale (1=no problems, 2=some problems and 3=severe problems). Respondents are asked to choose one level that reflects their "own health state today" for each of the five dimensions.

    Time frame: Day 168/Week 24

  6. Change From Baseline in EQ-5D Visual Analog Scale (VAS) Score at Day 168

    The EQ-5D is a standardized, 2-part, self-assessment instrument, designed for self-completion, used to measure health outcome. The first part consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). The second part is a 20 centimeter VAS that has endpoints labelled "best imaginable health state" and "worst imaginable health state" anchored at 100 and 0, respectively. Participants were asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS that best represents their own health on that day. Analysis was performed using ANCOVA with covariates of Baseline VAS score, country, sex, age, and treatment.

    Time frame: Baseline and Day 168

07

Results

Posted Sep 5, 2013

Participant flow

Run-in Period
Participant flow — Run-in Period
MilestoneFluticasone Propionate 250 µg BIDFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
Started156400
Completed80600
Not completed75800
Withdrew: Screen failure62300
Withdrew: Run-in failure13500
Randomized Phase
Participant flow — Randomized Phase
MilestoneFluticasone Propionate 250 µg BIDFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
Started0403403
Completed0358357
Not completed04546
Withdrew: Adverse event068
Withdrew: Lack of efficacy02011
Withdrew: Protocol violation0710
Withdrew: Lost to follow-up057
Withdrew: Physician decision001
Withdrew: Withdrawal by subject079

Outcome measures

PrimaryChange From Baseline in Weighted-mean 24 Hour Serial FEV1 on Day 168/Week 24

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second. The weighted mean was calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, on Day 168/Week 24. Change from Baseline was calculated as the weighted mean of the 24-hour serial FEV1 measures on Day 168/Week 24 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.

Time frame:
Baseline and Day 168/Week 24
Reported as:
Least squares mean · Liters
Change From Baseline in Weighted-mean 24 Hour Serial FEV1 on Day 168/Week 24
LitersFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
Change From Baseline in Weighted-mean 24 Hour Serial FEV1 on Day 168/Week 240.341 ± 0.01840.377 ± 0.0185
Statistical analysis
  • Fluticasone Furoate/Vilanterol 100/25 µg OD vs Fluticasone Propionate/Salmeterol 250/50 µg BID · ANCOVA · p = 0.162 · Least squares mean difference: -0.037 · 95% CI -0.088 to 0.015Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment.
SecondarySerial FEV1 (0-24 Hours)

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . The pre-dose FEV1 assessment and the individual serial FEV1 assessments at Day 168/Week 24 at the indicated time points (pre-dose, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 11 hours, 12 hours, 12.5 hours, 13 hours, 14 hours, 16 hours, 20 hours, 23 hours, and 24 hour s) were summarized.

Time frame:
Day 168
Reported as:
Mean · Liters
Serial FEV1 (0-24 Hours)
LitersFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
Pre-dose, n=359,3530.304 ± 0.35750.323 ± 0.4289
5 minutes, n=356, 3440.320 ± 0.35730.339 ± 0.4146
15 minutes, n=355, 3470.323 ± 0.35650.354 ± 0.4054
30 minutes, n=357, 3510.339 ± 0.36140.366 ± 0.4184
1 hour, n=358, 3530.344 ± 0.37600.390 ± 0.4227
2 hours, n=359, 3530.362 ± 0.37490.409 ± 0.4204
3 hours, n=357, 3530.373 ± 0.37640.419 ± 0.4173
4 hours, n=357, 3540.356 ± 0.36950.417 ± 0.4254
11 hours, n=359, 3470.305 ± 0.37610.319 ± 0.4099
12 hours, n=356, 3540.330 ± 0.36910.338 ± 0.4142
12.5 hours, n=357, 3520.330 ± 0.36820.380 ± 0.4117
13 hours, n=354, 3540.343 ± 0.36020.396 ± 0.4139
14 hours, n=356, 3530.357 ± 0.36430.426 ± 0.4201
16 hours, n=354, 3500.351 ± 0.36720.419 ± 0.4152
20 hours, n=355, 3520.321 ± 0.37570.376 ± 0.4150
23 hours, n=354, 3530.310 ± 0.38140.344 ± 0.4141
24 hours, n=354, 3540.304 ± 0.37250.340 ± 0.4032
SecondaryNumber of Participants With the Indicated Time to Onset of Bronchodilator Effect at Day 1

Time to onset of bronchodilator effect at Day 1 is defined as the actual time during the 4-hour serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) measurements that the participant first meets or exceeds a 12% and 200 mL increase over Baseline and was derived at Day 1 only. Time to onset was calculated over 0 to 4 hours (5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, and 4 hours) post-dose. Participants who never exceeded a 12% and 200 mL increase over Baseline were censored at the actual time of their last FEV1 measurement.

Time frame:
Baseline to Day 1
Reported as:
Number · participants
Number of Participants With the Indicated Time to Onset of Bronchodilator Effect at Day 1
participantsFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
5 minutes10085
15 minutes4151
30 minutes4055
1 hour3239
2 hours1929
3 hours1712
4 hours1112
Censored140118
SecondaryChange From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours Post First Dose (at Randomization)

The weighted mean serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) over 0-4 hours post-dose at Baseline was derived using actual times and using the pre-dose assessment as the 0 hour measurement. Change from Baseline was calculated as the weighted mean of the 4-hour serial FEV1 measures on Day 1 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment.

Time frame:
Baseline and Randomization
Reported as:
Least squares mean · Liters
Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours Post First Dose (at Randomization)
LitersFFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours Post First Dose (at Randomization)0.316 ± 0.01490.346 ± 0.0149
SecondaryChange From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours at Day 168

The weighted mean serial FEV1 (the maximal amount of air that can be forcefully exhaled in one second) over 0-4 hours post-dose at Baseline and Day 168 was derived using actual times and using the pre-dose assessment as the 0 hour measurement. Change from Baseline was calculated as the weighted mean of the 4-hour serial FEV1 measures on Day 168/Week 24 minus the Baseline value. Baseline was the pre-dose measurement on Day 1. Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment.

Time frame:
Baseline and Day 168
Reported as:
Mean · Liters
Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours at Day 168
LitersFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
Change From Baseline in Weighted Mean Serial FEV1 Over 0-4 Hours at Day 1680.360 ± 0.01840.394 ± 0.0186
SecondaryNumber of Participants Obtaining a >=12% and >=200 mL Increase From Baseline in FEV1

The number of participants obtaining a \>=12% and \>=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated at 12-hours post-dose and at 24-hours post-dose on Day 168.

Time frame:
Baseline and Day 168
Reported as:
Number · participants
Number of Participants Obtaining a >=12% and >=200 mL Increase From Baseline in FEV1
participantsFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
12 hours post-dose, n=356,354199178
24 hours post-dose, n=354, 354181176
SecondaryChange From Baseline in Trough FEV1 at Day 168

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . Trough FEV1 is defined as the pre-dose measurement on Day 168/Week 24. Any missing data at Day 168/Week 24 was imputed using the last observation carried forward (LOCF). Baseline was the pre-dose measurement on Day 1. Change from Baseline was calculated as the pre-dose measurement on Day 168/Week 24 minus the Baseline value.

Time frame:
Baseline and Day 168
Reported as:
Least squares mean · Liters
Change From Baseline in Trough FEV1 at Day 168
LitersFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
Change From Baseline in Trough FEV1 at Day 1680.281 ± 0.01910.300 ± 0.0193
Other pre-specifiedBaseline FEV1 by Completion Status

Pulmonary function was measured by FEV1, defined as the maximal amount of air that can be forcefully exhaled in one second . Baseline is defined as the mean of the two assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1.

Time frame:
Baseline
Reported as:
Mean · Liters
Baseline FEV1 by Completion Status
LitersFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
All Participants, n=401, 4012.011 ± 0.63892.048 ± 0.6246
Completers, n=359, 3552.013 ± 0.65302.043 ± 0.6378
Withdrawals, n=42, 461.996 ± 0.50812.091 ± 0.5145
Other pre-specifiedChange From Baseline in Asthma Control Test (ACT) Scores at Day 168

The ACT is a 5-item questionnaire developed as a measure of the participant's asthma control. Questions are designed to be self-completed by the participant and include the following: In the past 4 weeks, "How much of the time did your asthma keep you from getting as much done at work, school or at home?", "How often have you had shortness of breath?", "How often did your asthma symptoms wake you up at night or earlier than usual in the morning?", "How often have you used your rescue inhaler or nebulizer medication (such as albuterol)?" and "How would you rate your asthma control"? The ACT total score is defined as the sum of the scores from all 5 questions, provided all questions have been answered; thus, the total score ranges from 5 (poor control of asthma) to 25 (complete control of asthma). A score of 20 or higher indicates well-controlled asthma. Change from Baseline was calculated as the Day 168 value minus the Baseline value.

Time frame:
Baseline and Day 168
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Asthma Control Test (ACT) Scores at Day 168
Scores on a scaleFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
Change From Baseline in Asthma Control Test (ACT) Scores at Day 1682.3 ± 0.162.0 ± 0.16
Other pre-specifiedNumber of Healthcare Contacts Related to Asthma or the Treatment of Asthma From Baseline to Day 168

All unscheduled asthma-related visits to a physician's office, visits to urgent care, visits to the emergency department, and hospitalizations (to the general ward \[GW\] or the intensive care unit \[ICU\]) that were associated with asthma exacerbations were recorded.

Time frame:
Baseline to Day 168
Reported as:
Mean · visits per participant
Number of Healthcare Contacts Related to Asthma or the Treatment of Asthma From Baseline to Day 168
visits per participantFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
Number of Home Visits during the Day0.0 ± 0.00.0 ± 0.05
Number of Home Visits during the Night0.0 ± 0.00.0 ± 0.0
Number of Physician Office/Practice Visits0.0 ± 0.290.0 ± 0.18
Number of Urgent Care/Outpatient Clinic Visits0.0 ± 0.050.0 ± 0.05
Number of Emergency Room Visits0.0 ± 0.150.0 ± 0.14
Number of Inpatient Hospitalization (ICU) Days0.0 ± 0.000.0 ± 0.0
Number of Inpatient Hospitalization (GW) Days0.0 ± 0.200.0 ± 0.39
Other pre-specifiedChange From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score for Participants 12 Years of Age and Older (AQLQ + 12)

The AQLQ is a disease-specific, self-administered quality of life (QOL) questionnaire developed to evaluate the impact of asthma treatments on the QOL of asthma sufferers. The AQLQ contains 32 items in four domains: activity limitation (11 items), symptoms (12 items), emotional function (5 items), and environmental stimuli (4 items). The response format consists of a 7-point scale: a value of 1 indicates "total impairment"; a value of 7 indicates "no impairment." The AQLQ total score is defined as the average of the scores from all 32 questions, provided at least 90% of the questions have been answered; thus, the total score ranges from 1 (indicates "total impairment") to 7 (indicates "no impairment"). Change from Baseline was calculated as the Day 168 value minus the Baseline value. Analysis was performed using ANCOVA with covariates of Baseline total AQLQ score, country, sex, age, and treatment.

Time frame:
Baseline and Day 168
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score for Participants 12 Years of Age and Older (AQLQ + 12)
Scores on a scaleFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Total Score for Participants 12 Years of Age and Older (AQLQ + 12)0.46 ± 0.0430.37 ± 0.043
Other pre-specifiedPercentage of Participants With "No Problems" in the EQ-5D Descriptive System Dimensions at Day 168/Week 24

The EQ-5D is a standardized, 2-part, self-assessment instrument, designed for self-completion, used to measure health outcome. The first part consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). Each dimension is measured by a three-point Likert scale (1=no problems, 2=some problems and 3=severe problems). Respondents are asked to choose one level that reflects their "own health state today" for each of the five dimensions.

Time frame:
Day 168/Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With "No Problems" in the EQ-5D Descriptive System Dimensions at Day 168/Week 24
percentage of participantsFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
Mobility8684
Self care9898
Usual activities8682
Pain/Discomfort7066
Anxiety/Depression7881
Other pre-specifiedChange From Baseline in EQ-5D Visual Analog Scale (VAS) Score at Day 168

The EQ-5D is a standardized, 2-part, self-assessment instrument, designed for self-completion, used to measure health outcome. The first part consists of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). The second part is a 20 centimeter VAS that has endpoints labelled "best imaginable health state" and "worst imaginable health state" anchored at 100 and 0, respectively. Participants were asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS that best represents their own health on that day. Analysis was performed using ANCOVA with covariates of Baseline VAS score, country, sex, age, and treatment.

Time frame:
Baseline and Day 168
Reported as:
Least squares mean · scores on a scale
Change From Baseline in EQ-5D Visual Analog Scale (VAS) Score at Day 168
scores on a scaleFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
Change From Baseline in EQ-5D Visual Analog Scale (VAS) Score at Day 1685.5 ± 0.604.1 ± 0.60

Adverse events

Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of the study medication until Follow-up (up to 544 days).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fluticasone Furoate/Vilanterol 100/25 µg OD—4/403 (1%)110/403 (27.3%)
Fluticasone Propionate/Salmeterol 250/50 µg BID—5/403 (1.2%)106/403 (26.3%)
Most frequent serious events
Most frequent serious events
EventFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
AsthmaRespiratory, thoracic and mediastinal disorders1/4032/403
PneumoniaInfections and infestations0/4031/403
Upper respiratory tract infectionInfections and infestations1/4030/403
Urinary tract infectionInfections and infestations0/4031/403
Myocardial ischaemiaCardiac disorders1/4030/403
CholelithiasisHepatobiliary disorders1/4030/403
Carbon monoxide poisoningInjury, poisoning and procedural complications0/4031/403
DisorientationPsychiatric disorders0/4031/403
Most frequent other events
Most frequent other events
EventFluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BID
NasopharyngitisInfections and infestations46/40346/403
HeadacheNervous system disorders34/40341/403
Upper respiratory tract infectionInfections and infestations25/40316/403
CoughRespiratory, thoracic and mediastinal disorders15/40313/403
PyrexiaGeneral disorders13/4035/403

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Fluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BIDTotal
Mean43.8 ± 15.8641.9 ± 16.9042.8 ± 16.41
Gender
Gender(Participants)Fluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BIDTotal
Female244245489
Male159158317
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Fluticasone Furoate/Vilanterol 100/25 µg ODFluticasone Propionate/Salmeterol 250/50 µg BIDTotal
African American/African Heritage364379
Asian - Central/South Asian Heritage101
Asian - East Asian Heritage404686
Asian - Japanese Heritage101
Asian - South East Asian Heritage8179160
Asian - Mixed Race101
Native Hawaiian or Other Pacific Islander112
White - Arabic/North African Heritage101
White - White/Caucasian/European Heritage241232473
Mixed Race022
08

Study locations

63 sites
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Rolling Hills Estates, California 90274, United States
  • GSK Investigational Site
    San Diego, California 92117, United States
  • GSK Investigational Site
    Centennial, Colorado 80112, United States
  • GSK Investigational Site
    Denver, Colorado 80230, United States
  • GSK Investigational Site
    Cocoa, Florida 32927, United States
  • GSK Investigational Site
    Bethesda, Maryland 20814, United States
  • GSK Investigational Site
    Wheaton, Maryland 20902, United States
  • GSK Investigational Site
    Rolla, Missouri 65401, United States
  • GSK Investigational Site
    St. Louis, Missouri 63141, United States
  • GSK Investigational Site
    Cherry Hill, New Jersey 08003, United States
  • GSK Investigational Site
    Skillman, New Jersey 08558, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Austin, Texas 78750, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Waco, Texas 76712, United States
  • GSK Investigational Site
    Quilmes, Buenos Aires B1878FNR, Argentina
  • GSK Investigational Site
    Parana, Entre Ríos E3100BHK, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2000DSR, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2000JKR, Argentina
  • GSK Investigational Site
    Buenos Aires, 1425, Argentina
  • GSK Investigational Site
    Buenos Aires, C1424BSF, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425BEN, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Mendoza, M5500CCG, Argentina
  • GSK Investigational Site
    San Miguel de Tucumán, 4000, Argentina
  • GSK Investigational Site
    Rancagua, Reg Del Libert Bern Ohiggins 2841959, Chile
  • GSK Investigational Site
    Puente Alto - Santiago, Región Metro De Santiago 8207257, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7500691, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 7601003, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago, Chile
  • GSK Investigational Site
    Valparaiso, Valparaíso 2341131, Chile
  • GSK Investigational Site
    Viña del Mar, Valparaíso, Chile
  • GSK Investigational Site
    Cheongju, Chungcheongbuk-do, 361-711, Korea, Republic of
  • GSK Investigational Site
    Incheon, 400-711, Korea, Republic of
  • GSK Investigational Site
    Kangwon-do, 220-701, Korea, Republic of
  • GSK Investigational Site
    Seoul, 110-744, Korea, Republic of
  • GSK Investigational Site
    Seoul, 135-710, Korea, Republic of
  • GSK Investigational Site
    Seoul, 138-736, Korea, Republic of
  • GSK Investigational Site
    Suwon, Kyonggi-do, 443-721, Korea, Republic of
  • GSK Investigational Site
    Almelo, 7609 PP, Netherlands
  • GSK Investigational Site
    Breda, 4819 EV, Netherlands
  • GSK Investigational Site
    Dordrecht, 3318 AT, Netherlands
  • GSK Investigational Site
    Eindhoven, 5623 EJ, Netherlands
  • GSK Investigational Site
    Harderwijk, 3844 DG, Netherlands
  • GSK Investigational Site
    Heerlen, 6419 PC, Netherlands
  • GSK Investigational Site
    Hoorn, 1624 NP, Netherlands
  • GSK Investigational Site
    Veldhoven, 5504 DB, Netherlands
  • GSK Investigational Site
    Cabanatuan City, Nueva Ecija, 3100, Philippines
  • GSK Investigational Site
    Cebu City, 6000, Philippines
  • GSK Investigational Site
    Dasmariñas, Cavite, 4114, Philippines
  • GSK Investigational Site
    Manila, 1000, Philippines
  • GSK Investigational Site
    Marilao, Bulacan, 3019, Philippines
  • GSK Investigational Site
    Quezon City, 1100, Philippines
09

References and documents

Publications

  • Woodcock A, Bleecker ER, Lotvall J, O'Byrne PM, Bateman ED, Medley H, Ellsworth A, Jacques L, Busse WW. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest. 2013 Oct;144(4):1222-1229. doi: 10.1378/chest.13-0178. PubMed 23846316 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 2 years 2 months after primary completion. A results delay was requested in Mar 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2010
First posted
Jun 22, 2010
Start
Jun 2010
Primary completionActual
Jul 2011
CompletionActual
Jul 2011
Results delay requested
Mar 1, 2012
Results first posted
Sep 5, 2013
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01147848
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 22, 2010
Start date
Jun 2010
Primary completion
Jul 2011
Completion
Jul 2011
Results posted
Sep 5, 2013
Last update
Jan 18, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion